Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents

Current Pharmaceutical Design

Volumn 10, Issue 25, 2004, Pages 3111-3119

  Lahiri, D K ^a   Rogers, J T ^b   Greig, N H ^c   Sambamurti, K ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Anticholinesterase; ApoE; APP gene; BACE; Beta amyloid; Butyrylcholine; Cholinergic agents; Cholinesterase; Cholinomimetic drugs; Dementia; Oxidative stress; Phenserine; Secretase; Tau protein

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MUSCARINIC AGENT; NOOTROPIC AGENT; PHENSERINE; PRESENILIN 1; PRESENILIN 2; RIVASTIGMINE; TACRINE;

5' UNTRANSLATED REGION; ALZHEIMER DISEASE; CHOLINERGIC STIMULATION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DRUG TARGETING; ENZYME ACTIVITY; FOREBRAIN; GENE MUTATION; HUMAN; IN VITRO STUDY; LEARNING; MEDICAL RESEARCH; MEMORY; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN SECRETION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 4544295150     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383331     Document Type: Review

References (83)

1. Alzheimer's Association, Chicago, IL: web site http://www.alz.org/
2. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003; 4(2): 97-112.
3. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alz Dis Assoc Disord 2001; 15(4): 169-73.
4. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43: 545-84.
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297(5580): 353-6.
6. Terry RD. The cytoskeleton in Alzheimer disease. J Neural Transm Suppl 1998; 53: 141-5,
7. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217(4558): 408-14.
8. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2(8000): 1403.
9. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4(4): 273-7.
10. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60(9): 1495-500.
11. Grundke-Iqbal I, Iqbal K. Tau pathology generated by overexpression of tau, Am J Pathol 1999; 155(6): 1781-5.
12. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001; 32(2): 181-4.
13. Roses AD, Pangalos MN. Drug development and Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 123-30.
14. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromol Med 2002; 1(1): 1-31.
15. Sisodia SS. Biomedicine. A cargo receptor mystery APParently solved? Science 2002; 295(5556): 805-7.
16. Holtzman DM, Li YW, DeArmond SJ, McKinley MP, Gage FH, Epstein CJ, et al. Mouse model of neurodegeneration: atrophy of basal forebrain cholinergic neurons in trisomy 16 transplants. Proc Natl Acad Sci USA 1992; 89(4): 1383-7.
17. Price DL, Sisodia SS, Borchelt DR. Genetic neurodegenerative diseases: the human illness and transgenic models. Science 1998; 282(5391): 1079-83.
18. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002; 22(5): 1858-67.
19. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Nat Acad Sci USA 1999; 96(26): 15233-8.
20. Bush AI, Tanzi RE. The galvanization of beta-amyloid in Alzheimer's disease. Proc Nat Acad Sci USA 2002; 99(11): 7317-9.
21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274(5284): 99-102.
22. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283(12): 1571-7.
23. Neve RL, Robakis NK. Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends in Neurosci 1998; 21(1): 15-9.
24. Neve RL, McPhie DL, Chen Y. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein? Biochem Soc Symp 2001(67): 37-50.
25. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990; 250(4978): 279-82.
26. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA 2003; 100(11): 6382-7.
27. Haass C, Steiner H. Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol 2002; 12(12): 556-62.
28. Marlow L, Canet RM, Haugabook SJ, Hardy JA, Lahiri DK, Sambamurti K. APH1, PEN2, and Nicastrin increase Abeta levels and gamma-secretase activity. Biochem Biophys Res Commun 2003; 305(3): 502-9.
29. Nitsch RM, Growdon JH. Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. Biochem Pharmacol 1994; 47(8): 1275-84.
30. Roberson MR, Harrell LE. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Rev 1997; 25(1): 50-69.
31. Mills J, Reiner PB. Regulation of amyloid precursor protein cleavage. J Neurochem 1999; 72(2): 443-60.
32. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258(5080): 304-7.
33. Hung AY, Haass C, Nitsch RM, Qiu WQ. Citron M, Wurtman RJ, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 1993, 268(31): 22959-62.
34. Wolf BA, Wertkin AM, Jolly YC, Yasuda RP, Wolfe BB, Konrad RJ, et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 1995; 270(9): 4916-22.
35. Hellstrom-Lindahl E. Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 2000; 393(1-3): 255-63.
36. Kim SK, Kim YK, Jeong SJ, Haass C, Kim YH, Suh YH. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol Pharmacol 1997; 52: 430-6,
37. Utsuki T, Shoaib M, Holloway HW, Ingram DK, Wallace WC, Haroutunian V, et al. Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. J Alzheimers Dis 2002; 4(5): 405-15.
38. Lahiri DK, Utsuki T, Chen D, Farlow MR, Shoaib M, Ingram DK, et al. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins. Ann NY Acad Sci 2002; 965: 364-72.
39. Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci USA 1994; 91(10): 4489-93.
40. Loffler J, Huber G. Modulation of beta-amyloid precursor protein secretion in differentiated and nondifferentiated cells. Biochem Biophy Res Comm 1993; 195(1): 97-103.
41. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand (suppl) 2000; 176: 60-7.
42. Racchi M, Sironi M, Caprera A, Konig G, Govoni S. Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 2001; 6(5): 520-8.
43. Racchi M, Govoni S. The pharmacology of amyloid precursor protein processing. Exp Gerontology 2003; 38(1-2): 145-57.
44. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. NeuroReport 1995; 6(4): 633-6.
45. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 1994; 37(6): 777-87.
46. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986; 47(1): 263-77.
47. Soreq H, Seidman S. Acetylcholinesterase-new roles for an old actor. Nature Rev Neurosci 2001; 2(4): 294-302.
48. Lahiri DK. Alzheimer's disease-current trends in basic and clinical research. Highlights from the 16th ECNP. September 20-24 2003, Prague, Czech Republic. Expert Opin Investig Drugs 2004; 13(1): 79-86.
49. Becker RE, Moriearty P, Unni L, Vicari S. In: Becker R, Giacobini E Eds, Alzheimer's disease: from molecular biology to therapy. Boston, Birkhäuser, 1977; 257-266.
50. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003; 28(3-4): 515-22.
51. Lahiri DK, Farlow MR, Greig NH,.Sambamurti K. Current drug targets for Alzheimer's disease treatment. Drug Dev Res 2002; 56(3): 267-281.
52. Mesulam M. In: Giacobini E Ed, Cholinesterases and cholinesterase inhibitors. London, Martin Dunitz, 2000; 121-136.
53. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002; 14(Suppl 1): 77-91.
54. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4(2): 131-8.
55. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17(3): 159-65.
56. Lahiri DK, Farlow MR, Ge Y, Sambamurti K, Utsuki T, Greig NH. In: Mizuno Y, Fisher A, Hanin I Eds, Mapping the progress of Alzheimer's and Parkinson's disease, New York, Kluwer Academic/Plenum Publishers, 2002; 211-216.
57. Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, et al. Pharmacological modulation of Alzheimer's bcta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Mol Brain Res 1997; 46(1-2): 161-8.
58. Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Mol Brain Res 1998; 62(2): 131-40.
59. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, et al. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Nat Acad Sci USA 2001; 98(13): 7605-10.
60. Arendt T, Bruckner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int 1992; 21(3): 381-96.
61. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neurosci 2002; 110(4): 627-39.
62. Geula C, Mesulam MM. In: Bick KL, Katzman R, Terry RD Eds, Alzheimer disease. New York, Raven Press Ltd, 1994; 263-291.
63. Moran MA, Mufson EJ, Gomez-Ramos P. Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol 1993; 85(4): 362-9.
64. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997; 272(3): 348-61.
65. Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ, Calderon FH, et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 1998; 18(9): 3213-23.
66. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochem 2001; 40(35): 10447-57.
67. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16(4): 881-91.
68. Cottingham MG, Hollinshead MS, Vaux DJ. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry 2002; 41(46): 13539-47.
69. Hu W, Gray NW, Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J Neurochem 2003; 86(2): 470-8.
70. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 2003; 24(6): 777-87.
71. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, et al. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989; 86(19): 7606-10.
72. Lahiri DK, Nall C. Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Mol Brain Res 1995; 32(2): 233-40.
73. Buxbaum JD, Greengard P. Regulation of APP processing by intra- and intercellular signals. Ann NY Acad Sci 1996; 777: 327-31.
74. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 1999; 274(10): 6421-31.
75. Lahiri DK, Chen D, Vivien D, Ge YW, Greig NH, Rogers JT. Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer's disease. J Alzheimers Dis 2003; 5(2): 81-90.
76. Kar S. Role of amyloid β peptides in the regulation of central cholinergic function and its relevance to Alzheimer's disease pathology. Drug Dev Res 2002; 56: 248-63.
77. Sambamurti K, Hardy J, Refolo, LM, Lahiri DK. Targeting APP metabolism for the treatment of Alzheimer's disease. Drug Dev Res 2002; 56(2): 211-227.
78. Sambamurti K, Granholm AC, Kindy MS, Bhat NR, Greig N, Lahiri DK, et al. Cholesterol and Alzheimer's Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors. Curr Drug Targets 2004; 5(6): 517-528.
79. Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 2004; 5(6): 535-552.
80. Lahiri DK, Sambamurti K, Bennett DA. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies with Alzheimer's disease. Neurobiol Aging 2004; 25(5): 651-660.
81. Conway KA, Baxter EW, Felsenstein KM, Reitz AB. Emerging beta-amylbid therapies for the treatment of Alzheimer's disease. Curr Pharm Design 2003; 9(6): 427-47.
82. Gualtieri F, Manetti D, Romanelli MN, Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Design 2002; 8(2): 125-38.
83. Schimmoller F, Higaki JN, Cordell B. Amyloid forming proteases: therapeutic targets for Alzheimer's disease. Curr Pharm Design 2002; 8(28): 2521-31.